Jan 17 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it had approved the first generic version of Xyrem, Jazz Pharmaceuticals Plc's drug to treat patients with a medical condition that causes excessive daytime sleepiness. (http://bit.ly/2jHzIS9)
Jazz Pharma's shares were down 4.8 percent at $110 in extended trading.
(Reporting by Divya Grover in Bengaluru; Editing by Maju Samuel)
"We are not very ambitious. I should be careful about talking about work-life balance, but the Americans just work harder.”
In his 2016 letter to Berkshire Hathaway shareholders, legendary investor Warren Buffett wrote, “Every decade or so, dark clouds will fill the economic skies, and they will briefly rain gold. When downpours of that sort occur, it’s imperative that we ...
Intel stock dropped 9% after the company reported Q1 earnings. Is it a buy right now?
Microsoft reported better than anticipated Q3 earnings on Thursday, powered by growth in its cloud products.
The combination of artificial intelligence (AI) and cybersecurity is a match made in heaven.
Gross said in a post on X to avoid tech, but if you have to invest in the sector, one name stands out.
As US growth shows signs of sputtering and inflation keeps rising, a re-run of the tumultuous 1970s is looking more likely.
Rooting for Donald Trump to fail has rarely been this profitable. Just ask a hardy band of mostly amateur Wall Street investors who have collectively made tens of millions of dollars over the past month by betting that the stock price of his social media business — Truth Social — will keep dropping despite massive buying by Trump loyalists and wild swings that often mirror the candidate’s latest polls, court trials and outbursts on Trump Social itself.
Car-rental operator Hertz reported it lost another $200 million due to its EV gamble.
These stocks all deserve to be trading at far higher prices, and it may not be too long before they start to rally.